← Back to Search

GLP-1 RA agonist

Tirzepatide for Type 2 Diabetes

Phase 4
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment 12 weeks
Follow Up 0 days
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group

Summary

This trial is testing a new medication called tirzepatide for people with type 2 diabetes. Tirzepatide helps control blood sugar by making the body produce more insulin and reducing appetite. The study aims to see if switching to this new treatment is more effective than current therapies.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ 12 weeks
Follow Up ~0 days
This trial's timeline: 3 weeks for screening, 12 weeks for treatment, and 0 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in Hemoglobin A1c (HbA1c)
Secondary study objectives
Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values are >180 mg/dl (10 mmol/L)
Change from Baseline in Fasting Serum Glucose (FSG)
Change from Baseline in Percentage of Time per Day that Continuous Glucose Monitoring (CGM)-derived Values are >180 mg/dl (10 mmol/L)
+2 more

Side effects data

From 2022 Phase 3 trial • 210 Patients • NCT05024032
40%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Vomiting
11%
Gastroenteritis
9%
Flatulence
9%
Abortion induced
7%
Abdominal pain upper
7%
Gingivitis
7%
Amylase increased
7%
Lipase increased
6%
Abdominal pain
6%
Injection site reaction
6%
Menstruation irregular
4%
Hepatic function abnormal
4%
Hyperuricaemia
3%
Uterine polyp
3%
Vaginal infection
3%
Dizziness
1%
Hand fracture
1%
Supraventricular tachycardia
1%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
10 mg Tirzepatide
15 mg Tirzepatide

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TirzepatideExperimental Treatment1 Intervention
Participants will receive tirzepatide subcutaneously (SC).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~7520

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,657 Previous Clinical Trials
3,224,740 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,380 Previous Clinical Trials
423,594 Total Patients Enrolled

Media Library

Tirzepatide (GLP-1 RA agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05706506 — Phase 4
Type 2 Diabetes Research Study Groups: Tirzepatide
Type 2 Diabetes Clinical Trial 2023: Tirzepatide Highlights & Side Effects. Trial Name: NCT05706506 — Phase 4
Tirzepatide (GLP-1 RA agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05706506 — Phase 4
Type 2 Diabetes Patient Testimony for trial: Trial Name: NCT05706506 — Phase 4
~58 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top